A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.
Relapsed / Refractory Follicular Lymphoma
DRUG: TQ-B3525
Objective response rate (ORR) assessed by Independent Review Committee (IRC), Percentage of subjects achieving complete response (CR) and partial response (PR) based on IRC., Baseline up to 18 months
Progression-free survival (PFS), PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause., Baseline up to 18 months|Overall response rate (ORR) assessed by investigator, Percentage of subjects achieving complete response (CR) and partial response (PR) based on investigator., Baseline up to 18 months|Disease control rate（DCR）, Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)., Baseline up to 18 months|Overall Survival (OS), OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up., Baseline up to 24 months|Disease control rate (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., Baseline up to 18 months|Safety, AE, ADR, and SAE, and withdrawal from the trial for reasons such as safety or tolerability., Baseline up to 18 months|Biomarkers, To assess the changes of genes related to PI3K pathway and bypass in the tissues and / or plasma of enrolled patients., Baseline up to 18 months
The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.